NUVECTIS PHARMA INC (NVCT)
US67080T1088 - Common Stock
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Thursday?
Which stocks are moving on Thursday?
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Thursday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Curious about the stocks that are showing activity before the opening bell on Thursday?
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
What's going on in today's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient...
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical...
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
Precision Medicine M&A is Transforming the Future of the Biotech Industry
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track...
Nuvectis Pharma is Now Oversold (NVCT)
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single...
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed...
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
NVCT stock results show that Nuvectis Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nuvectis Pharma (NASDAQ:NVCT) just reported results for the fourth quarter of 2...
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been...